

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

<https://marketpublishers.com/r/CDA0684C1AFEN.html>

Date: June 2019

Pages: 121

Price: US\$ 900.00 (Single User License)

ID: CDA0684C1AFEN

Abstracts

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

This Competitive Intelligence report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseases as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019.

At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditional application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).

The report highlights the use of bispecific antibody technology for generation of

T-Cell Redirecting Bispecific Antibodies

Bispecific Natural Killer (NK) Cell Redirecting Antibodies

Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies

Bispecific Immuno-Oncology Antibodies

Bispecific Tumor Associated Antigen (TAA)/Growth Factor Targeted Antibodies

Bispecific Antibodies for Non-Cancer Indications

research and development of bispecific therapeutic antibodies in cancer and non-cancer indications. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Contents

1) T-CELL REDIRECTING BISPECIFIC ANTIBODIES

Targeting BCMA
Targeting CD20
Targeting CD19
Targeting CD33
Targeting CD123
Targeting PSMA
Targeting Her2
Targeting Mesothelin
Targeting CD38
Targeting EGF-R
Targeting DLL3
Targeting Various Other Cancer Surface Antigens
Targeting Not Disclosed Tumor Associated Antigens
Targeting (Intracellular) peptide/MHC Antigens
Novel Bispecific T-Cell Redirecting Antibody Constructs
Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases

2) BISPECIFIC NATURAL KILLER (NK) CELL REDIRECTING ANTIBODIES

3) BISPECIFIC T-CELL ENGAGING, CONDITIONAL COSTIMULATORY ANTIBODIES

Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
Bispecific, Dual Costimulatory Antibodies

4) BISPECIFIC IMMUNO-ONCOLOGY ANTIBODIES

Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
Bispecific Checkpoint Inhibitor & Costimulator Antibodies
Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies

Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
Bispecific, Not Specified Immuno-Oncology Antibodies

5) BISPECIFIC TUMOR ASSOCIATED ANTIGEN (TAA) / GROWTH FACTOR TARGETED ANTIBODIES –

Bispecific Her2-Targeted Antibodies
Bispecific VEGF-Targeted Antibodies
Other Bispecific TAA-Targeted Antibodies

6) BISPECIFIC ANTIBODIES FOR NON-CANCER INDICATIONS

Bispecific Inflammatory & Autoimmune Disease Antibodies
Bispecific Cardiometabolic Antibodies
Bispecific Ophthalmic Disease Antibodies
Bispecific Neurologic Disease Antibodies
Bispecific Infectious Disease Antibodies
Bispecific Antibodies For Targeted Delivery

I would like to order

Product name: Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

Product link: <https://marketpublishers.com/r/CDA0684C1AFEN.html>

Price: US\$ 900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDA0684C1AFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970